Do we need another heart failure biomarker. focus on soluble suppression of tumorigenicity 2 (sST2) by Maisel, Alan S & DI SOMMA, Salvatore
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
Dowe need another heart failure biomarker:
focus on soluble suppression of tumorigenicity
2 (sST2)
Alan S. Maisel1* and Salvatore Di Somma 2
1Division of Cardiology, San Diego Veterans Affairs Medical Center and University of California, Vamc 3350 La Jolla Village Drive, San Diego CA 92161, USA; and 2Department
of Medical-Surgery Sciences and Translational Medicine, Emergency Medicine Saint’ Andrea Hospital, School of Medicine and Psychology, “Sapienza” University, Rome, Italy
Received 17 August 2015; revised 17 August 2016; accepted 14 September 2016
Introduction: why use biomarkers
in the care of our heart failure
patients?
Managing patients with heart failure is no easy task. For those of us
who delve in the daily ‘fray’ of heart failure, there are a number of sit-
uations where appropriate use of biomarkers may lead to better
treatment:
(1) In patients presenting with dyspnoea, how sure are we of the diag-
nosis of heart failure?
(2) What treatments can I safely start in the hospital?
(3) How do I know the appropriate time to discharge a patient?
(4) Who is at high risk for early readmission and what can I do to pre-
vent it?
(5) How do I decide what dose of known cardiac medications to treat
with in the clinic?
(6) How do I determine if some of the newer heart failure drugs and
devices are appropriate-and cost effective—for my patient?
Biomarkers exist in part to help answer the above questions.
Biomarkers used for diagnosis should be either sensitive OR spe-
cific and much of the value may actually be on the low end to ‘rule
out’ disease. In this regard a B-type natriuretic peptide (BNP) level
under 100 pg/ml or an Nt-proBNP level< 300 pg/ml, rules out
acute heart failure in more than 9 out of 10 cases. A good bio-
marker is a surrogate for underlying pathophysiologic abnormal-
ities, and hence is often prognostic. However, in clinical practice
‘what to do about the biomarker value’ is often the make-or-
break question.1 The biomarkers that are here to stay are those
that we can act on: personalize treatment in such a way that we
might start a certain treatment or titrate that treatment using the
changing levels of the biomarker. Of course all this should remain
within the scope of clinical presentation of the patient along with
physician equipoise as well as other, adjunctive tests.
What biomarkers have we used?
The major biomarkers used for heart failure are the natriuretic pepti-
des (NPs): both BNP and Nt-proBNP are useful in diagnosis and ruling
out acute heart failure, can be used for risk stratification, and based on
the upcoming results of the GUIDE IT trial, may soon be used for out-
patient titration of cardiac medications.2–6 In the hospital we already
use NPs as a rough guide to volume management—using diuretics to
help achieve a transition from a high ‘wet’ NP level toward a more
euvolemic ‘dry’ NP may allow us to send a patient home fully decon-
gested. While this is somewhat simplified, it has worked well in our
practice. Additionally, a discharge NP level appears to be something
we can use to follow the patient as they transition to the outpatient
setting, both as a gauge when possible heart failure decompensation
occurs, as well as a way to manage the patient’s medications. But NPs
have their problems. They are affected not only by conditions such as
renal dysfunction, obesity, atrial fibrillation and anaemia, and levels can
be elevated in HFpEF, HFrEF, pulmonary hypertension and right heart
failure. Thus the level of NP should never be used as a stand-alone test,
but rather as an important adjunct to clinical judgment and other tests.
The same can be said for any test.
Cardiac troponins
While cardiac troponins are mainstays in the evaluation of chest pain,
their role in heart failure is yet to be fully ascertained.7–9 Clearly prog-
nostic in patients presenting with acute decompensated heart failure,
there are as of yet no algorithms for additional treatment strategies
based on troponin levels. With high sensitivity assays virtually all
Patients with acute decompensated heart failure will have levels
above the 99th percentile for the specific assays. The questions that
still need to be answered are:
(1) What level of elevation should one be suspicious of for a Type I
NSTEMI as the cause of heart failure?
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(2) Should we target specific anti-ischemic agents (nitrates or
ranolazine for example) towards rising troponins, and if so, what
delta troponin value should we use?
(3) Can we use troponins to help identify the aetiology of heart failure
such as infiltrative (amyloidosis) or inflammatory cardiomyopathy?
(4) What will the role of hs-Troponin levels be in ambulatory heart fail-
ure in relation to sST2 and Natriuretic peptides
Procalcitonin (PCT)
PCT is a robust indicator of bacterial infection that is released early in
response to bacteria and in amounts correlated to the severity of
infection.10 Levels decrease as effective therapy is instituted and may
in fact help guide the duration of antibiotic treatment.11 The BACH
study demonstrated the potential usefulness in patients admitted
with dyspnoea.12 PCT and BNP used together were able to separate
most patients who had heart failure, pneumonia, or both. In addition,
in patients who had low levels of PCT but were treated with antibiot-
ics had a worse prognosis than those not given antibiotics. Those
with high PCT levels and not given antibiotics also had a poor prog-
nosis. The IMPACT trial is underway to test the hypothesis that in
patients with dyspnoea, PCT can be used to guide treatment.
So do we need another
biomarker?
The pathway to validation of a new biomarker is long and arduous.
For the care and management of patients with heart disease very few
biomarkers have successfully traversed this path since NPs and tro-
ponin. sST2 is one such biomarker that has jumped through all the
‘hoops’ expected from a biomarker that is ready for clinical use.
Extensive clinical research studies have clearly demonstrated the util-
ity of sST2 as a biomarker,13 there is an food and drug administration
(FDA) cleared and validated assay available14 and it is noted in the
2013 American heart association (AHA) Heart Failure Guidelines. In
our experience it is the ONLY new, approved, and available bio-
marker that can be of value today in taking care of patients with both
acute and chronic heart failure. We have used sST2 clinically for the
past years and will present our experience here.
What is sST2?
ST2 is a member of the interleukin 1 receptor family also known as
interleukin 1 receptor-like 1 (IL1RL-1).15,16 ST2 stands for ‘suppres-
sion of tumorigenicity 2’. It was discovered in 198916 but only in 2002
Weinberg et al17 reported that it can be expressed by cardiac cells in
response to myocardial stress, drawing attention of researchers to a
role in the cardiovascular system. ST2 has two main isoforms: trans-
membrane or cellular (ST2L) and soluble or circulating (sST2)
form.17 ST2 is the receptor for interleukin-33 (IL-33), which is an
IL-1-like cytokine that is secreted by living cells in response to cell
damage. The interaction of IL-33 and sT2L has been proved to be
cardioprotective in experimental models, reducing myocardial fibro-
sis, cardiomyocyte hypertrophy and apoptosis. This cardioprotective
action occurs exclusively through the ST2L receptor and not through
the soluble form. In fact when the soluble receptor is shed in cases of
cardiac ‘distress, sST2 avidly binds to IL-33 competing with ST2L,
blocking the IL-33/ST2L system and eliminating the cardioprotective
effects described above. Therefore, sST2 is considered a decoy
receptor.18
As we began using sST2 in the hospital and the heart failure clinic,
I would often be asked: Why should we use sST2 when our present
way of managing heart failure is sufficient? The answer is both simple
and complex. Take the example of patients presenting with acute
heart failure. Most are treated exactly the same-meaning intravenous
followed by oral diuretics followed by discharge. Some patients do
fine; some are readmitted within 30 days; other die. The discouraging
fact here that it is difficult up front to tell which patient will suffer
which fate. High BNP levels (above the dry BNP) correlates with vol-
ume overload, which is often obvious to the physician. However, our
experience thus far suggests that sST2 levels give us insight into the
state of heart failure far beyond the state of intravascular volume or
physical exam findings. While it is certainly additive to what NPs bring
to the table, we believe that sST2 might potentially be looked at as
the HbA1c of heart failure (Figure 1); in other words, the sST2 value
has inputs from wall stress, inflammation, macrophage activation (fib-
rosis) and a number of still-to-be determined stimuli. Just as better
glucose control drops HbA1c levels into a better prognostic range,
better control of heart failure appears to lower sST2 levels.
Thus far, the level of sST2 does not appear to be significantly
affected by age, sex, BMI, aetiology of heart failure, atrial fibrillation
and anaemia. Unlike almost any cardiac biomarker in use, sST2 does
not appear to be significantly affected by renal function. The fact that
sST2 has the lowest intra-individual variation and smallest relative
change value compared to other biomarkers makes it suitable for
accurate serial measurements.19 Finally, in the outpatient setting, an
sST2 value of 35 ng/ml appears to be the level that one should aim
for in therapy.20
Using sST2 in the hospital
Our experience with sST2 in patients admitted to the hospital with
acute decompensated heart failure conforms to data permeating the
literature. It is a powerful predictor of short-term and long-term
adverse events. In the PRIDE study the prognostic utility of sST2 was
additive to that of NT-proBNP, such that patients with elevation of
both markers had the highest 1-year mortality rate (almost 40%).21
This relationship of sST2 with death emerged soon after enrolment
in the study and remained significant out to 4 years from presenta-
tion. In fact, high sST2 levels reclassified risk of death in patients with
low-NP levels. Conversely, in patients with an sST2 value below the
median concentration, NT-proBNP>1,000 pg/mL was not a predic-
tor of 1-year mortality.
It is noteworthy to comment on the comparison of ST2 measure-
ments with other biomarkers in the setting of acute decompensated
heart failure (ADHF). In a study with 5306 patients carried out by the
Global Research on Acute Conditions Team, among a great number
of biomarkers measured at admission in patients with ADHF, sST2
emerged as the strongest biomarker with the ability to reclassify
death risk beyond a clinical model. sST2 was the best predictor of
both 30-day and 1-year mortality.22 For a biomarker to be useful in
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..risk stratification and in guiding treatment in ADHF, the values must
change in appropriate directions with appropriate treatment. The
biologic variation and the low index of variation of ST2 make it a good
candidate for monitoring and possibly guiding therapy in ADHF.17 One
of the first studies to assess serial measurements of sST2 was carried
out by our group using an Research Use Only (RUO) sST2 assay.23 In
this study sST2 was measured on a daily basis in patients admitted with
ADHF. We demonstrated that this biomarker changes quickly in
response to effective treatment. When values did not decrease or
even increased, there was a high probability of dying by six months
More recently, similar results were obtained by Manzano et al24,
using the newer, validated PresageVR ST2 Assay. They found that
median concentrations of sST2 decreased from 62 to 44 ng/mL and
those patients with persistent elevation on Day 4 had a higher risk of
death. Finally, Breidthardt et al25 observed that sST2 values signifi-
cantly decreased from admission to 48 h, especially in those with
favourable outcomes, with a median reduction of 42% in survivors vs.
25% in non-survivors.
Of note, there are significant differences between the commer-
cially available RUO assays and the validated (CE Mark and FDA
cleared) Presage ST2 Assay.26,27 The most notable difference is abso-
lute sensitivity. The Presage ST2 Assay is several fold more sensitive,
which allows accurate measurement of ST2 across the entire natu-
rally occurring concentration range. And has been tested to verify
that it is not effected potential interfering substances, such as heparin.
Our experience with sST2
in the ADHF patient
Figure 2 depicts the value of both BNP and sST2 measured in the set-
ting of acute heart failure as part of the clinical routine. We then
looked for heart failure admission three months before and three
months after the admission. Data were extrapolated if patient had
not been followed by us for the entire six months. sST2 levels are
strongly correlated to previous and post admissions, even more so
than BNP. We also demonstrated a robust area under the ROC
curve for heart failure admissions for sST2, as compared to BNP.
This is now being referred to as a ‘frequent flyer index’.
Figure 3, depicts a patient whose sST2 levels decreased using a com-
bination of diuretics and angiotensin converting enzyme (ACE) inhibi-
tors. This patient who was obese had low BNP levels at admission and
throughout treatment. Thus, obesity precluded us using the NP level
but not the level of sST2
Figure 4 demonstrates that while sST2 levels were initially decreased
secondary to vigorous diuretic treatment, low levels were unable to
be maintained. This was likely due to the inability to up titrate medica-
tions because of hypotension. He had two subsequent admissions.
Finally, Figure 5 demonstrates a high sST2 level at admission with
the inability to bring the level down with medications. He had six
admissions in the past year, and will now be started on Entresto.
Note the variability in the BNP levels.
wall stresssST2 as a decoy 
receptor 
when elevated 
binds IL-33, 
effectively 
reducing the 
concentration of 
IL-33 that is 
available to 
ST2L, thus 
diminishing the 
cardioprotective 
effect of IL-33. fibrosis 
inflammation 
sST2-The HbA1c 
of Heart Failure 
Myocyte 
Figure 1 sST2 the HbA1c of heart failure.
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Early lessons learned using sST2
in ADHF
(1) sST2 levels when elevated in patients admitted for ADHF, point to
a very sick patient, even when NP levels are either not high, or after
they decrease during treatment.
(2) sST2 levels will fall rapidly with hospital treatment, but if levels are
still high at discharge they are still at risk.
(3) A level that falls less than 25% from admission may benefit from more
aggressive treatment. We are beginning to drive sST2 levels down by
adding medications such as spironolactone while in the hospital.
(4) Elevated sST2 levels are strongly predictive of future heart failure
admissions, and characterize the ‘frequent fliers’ better than NPs
Value of soluble ST2 in chronic
heart failure and use in the clinic
While many physicians use NP levels as a means of ‘personalizing’
outpatient treatment for heart failure, it is still a class IIb indication.
The GUIDE IT trial, which should be completed soon, is a large
randomized trial of targeting levels of NT-proBNP to under 1000 pg/
ml vs. standard of care.28
If positive, the guidelines favouring NP guided therapy will likely be
implemented. In our own practice, we routinely order an sST2 level
along with the BNP level in our ambulatory clinic patients. This is
based on sound evidence from the literature below.
Daniels et al 29 did an excellent job of summarizing the many clini-
cal cohorts of chronic heart failure, demonstrating a clear prognostic
capability of ST2 levels in the ambulatory setting. Numerous studies
demonstrate the symbiotic relationship between sST2 and the NPs
with regards to prognosis.30–32 In fact, studies have demonstrated
that the combination of sST2 and NT-proBNP have a performance
similar to the Seattle Heart Failure Model.33,34 sST2 appears to trump
all other biomarkers except NPs in the ambulatory heart failure set-
ting. Recently, Gruson et al evaluated the value of sST2 in addition to
NPs (BNP, NT-proBNP, and proBNP1-108) and conventional risk fac-
tors such as age, LV ejection fraction, and estimated glomerular filtra-
tion rate. ST2 was the strongest predictor of cardiovascular death.30
While Galectin 3 is an another robust marker of fibrosis, it does
not change significantly during the course of treatment. Head-
to-head comparison of these two biomarkers revealed that sST2 was
superior to galectin-3 in risk stratification and reclassification of
patients.35 (It is noteworthy that in the Barcelona study, the perform-
ance of sST2 was not influenced by renal function, as observed with
NT-proBNP. The inclusion of ST2 along with other biomarkers
improved the prediction in patients with renal failure even more than
in the whole population.36 Thus in patients with renal impairment,
the sST2 level may even be a better marker to follow than the natriu-
retic peptides.
Patient: M.
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Right now, in our clinical setting, we have the availability of not
only BNP and sST2 but troponins as well. A recent study by Miller
et al37 biomarkers were collected every 3 months over to years and
analysed in relation to death/cardiac transplantation and heart failure
an hospitalization. Time dependent analysis demonstrated that BNP
cTnT, and sST2, along with clinical variables demonstrated a relation-
ship to the endpoints in all biomarkers but Galectin 3.37 Interestingly,
only serial measurements of sST2 demonstrated incremental value in
reclassifying patients. Finally, we had data from own institution to go
on (Figure 6). We reported on 588 outpatients who were referred
for echocardiography. High sST2 levels were independently associ-
ated with 1-year mortality, even among the subgroup of 429 patients
with no history of HF. Importantly, no patient with an ST2 value
below the median levels died in the first 6 months of follow-up
Sampling sST2 in the clinic depends on assay precision as well as
the variability of the test result within the same patient. This biological
variation of sST2 was recently assessed by Wu et al17. The study
included 17 healthy subjects over a period of 8 weeks. They found
that the reference change value for ST2 was 30%, much lower than
observed with galectin-3 (60%) or NT-proBNP (92%). The index of
individuality (a measure to evaluate whether serial measurements add
significantly to a single assessment) for ST2 was 0.25, suggesting value
from serial measurements. In comparison, the same index for galectin-
3 was 1.0, indicating that galectin-3 is useless for serial measurements.
These data suggest that soluble sST2 is a potential biomarker for mon-
itoring and possibly guiding therapy in patients with HF.
A cut point of 35 ng/ml appears to
separate high-risk from low-risk
patients
A number of studies all point to this level as the proverbial ‘magic
number’ to strive for, much the same way we strive for NT-proBNP
levels< 1000 pg/ml and BNP levels< 100 pg/ml. Januzzi et al deter-
mined in the PROTECT trial that the more time a patient spent with
levels> 35 ng/ml the more cardiac remodelling was felt to occur.30 In
the Valsartan Heart Failure Trial (VAL-HeFT) an increase in sST2
concentrations from baseline to 12 months was an excellent predic-
tor of events.31 Finally, the effects of medications on sST2 serial meas-
urements in the PROTECT study were assessed.32 Those with
elevated baseline sST2 concentrations who achieved higher beta-
blocker doses had significantly lower risk of events than those titrated
to lower beta-blocker dose. Those with low ST2 levels and high
beta-blocker doses experienced the lowest rate of events.
Examples of sST2 and BNP in our
outpatient clinic
Figure 7 demonstrates cases followed in our outpatient clinic
Patient H. This is a patient whose discharge sST2 level was
extremely high. He was placed on high doses of beta-blocker and
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hydralazine was started. His sST2 level has dropped significantly and
within that time period did not have a readmission.
Patient K demonstrates a patient who had a low sST2 at discharge
and this stayed low on medical treatment, with no readmissions in
the next year. The BNP level remained high.
Patient C: This was a previously stable patient who recently decom-
pensated with a doubling of sST2. He was admitted two days later, at
which time Entresto was added. He stabilized and his sST2 decreased.
Patient B: We were unable to increase medications due to hypo-
tension. The BNP level dropped but the sST2 remained high. In five
months he had three admissions from clinic and then died.
Lessons learned using sST2 in
ambulatory heart failure clinic
(1) sST2 levels measured in the outpatient setting, will decrease as
effective treatment is added.
(2) A level <35 ng/ml or a response of> 50% decrease appears to be
associated with improvement in symptoms and prognosis
(3) High sST2 levels in the outpatient setting are predictive of events,
even when NP levels are low.
The future of sST2 levels
If sST2 indeed turns into the HbA1c of heart failure, its value should
increase exponentially in our management of patients with heart fail-
ure. Serial sST2 levels should allow us to titrate therapy and monitor
the clinical state of the patient. In addition, since sST2 is such a strong
marker of the risk of death, it would not be surprising to see a level
be used to make decisions when patients are on the cusp of such
therapies as ICD, CRT, CardioMems implantation and even left ven-
tricular assist devices.
A discussion about the use of biomarkers would not be complete
without mentioning the issue of surrogates for determining the ther-
apy effectiveness of some of the newer heart failure drugs. Novartis’s
EntrestoVR , the brand name for its recently CE marked and FDA
approved ARNI1 drug (previously known as LCZ696) and Servier’s
ivabradine drug CorlanorVR (marketed by Amgen in the USA), also CE
marked and FDA approved, while offering exciting potential benefits
to heart failure patients—even being hailed ‘game-changer’ drugs by
some—raises the thorny issue of cost vs. benefit. These new drugs
are several times the cost of the generics that have become the main-
stay of heart failure treatment, i.e. ACE inhibitors, angiotensin recep-
tor blocker (ARBs), beta-blockers, etc. Pushback is therefore
expected from payers.
Because sST2 changes rapidly with the underlying condition of the
patient, is not affected by normal confounding factors, and has a single
cut point, it may be ideally suited to help clinicians determine if these
newer mediations are effective for each patient, are improving quality
of life, and whether dosing needs to be titrated or changed.
The new reality of heart failure care is that while more treatment
options have opened up, which can literally be a lifesaver for millions
of patients, the burden on healthcare systems has skyrocketed.
Biomarkers, and particularly sST2, could offer physicians and payers a
way to bring treatment down to an individual patient level, providing
Figure 6 Survival of patients referred for echocardiography based on sST2 and BNP.
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..good, affordable care to those in need and can benefit from these
breakthroughs. For that and the many real-world examples shown
above, sST2 has a very bright future in heart failure care.
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